Trius Therapeutics Inc (TSRX) Return on Equity ROE from the second quarter 2013 to second quarter 2012 and annually, average high and low, overall ranking from Jun 30 2013 to Jun 30 2012 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Trius Therapeutics Inc  (TSRX)

Trius Therapeutics Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Trius Therapeutics Inc in the second quarter 2013?
Trius Therapeutics Inc recorded a cumulative net loss of $-69 million during 12 months ending in the second quarter 2013, resulting in a negative return on equity (ROE) of -112.41%.

Within the Biotechnology & Pharmaceuticals industry 15 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2013 from 0 to 1162.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2013)
II. Quarter		 (Mar 31 2013)
I. Quarter		 (Dec 31 2012)
IV. Quarter		 (Sep 30 2012)
III. Quarter		 (Jun 30 2012)
II. Quarter
Y / Y Equity Change -30.08 % -21.02 % 13.82 % -0.07 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -69 -64 -54 -40 -8
Return On Equity (TTM) -112.41 % -94.72 % -74.94 % -56.52 % -10.97 %
TSRX's Total Ranking # 1162 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 55 72 57 61 78
Seq. Equity Change -24.34 % 27.27 % -7.43 % -21.56 % -14.53 %
Seq. Net Income Change - - - - -

Back to TSRX Management Effectiveness >> TSRX's 5 Years Annual ROE >> Compare TSRX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 16
Sector # 80
Overall # 1162

Return On Equity Statistics
High Average Low
-74.94 %
-94.02 %
-112.41 %
(Dec 31 2012)   (Jun 30 2013)





TSRX Annual Return On Equity (Dec 31 2012)
2012		 (Dec 31 2011)
2011


Total Equity in Millions 57 50 0 0 0
Y / Y Equity Change 13.82 % - - - -
Net Income in Millions -54 -18 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity -94.97 % -36.58 % - - -

Back to TSRX Management Effectiveness >> TSRX's 5 Years Annual ROE >> Compare TSRX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TSRX's' Return on Equity at Yahoo Finance
TSRX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TSRX's Competitors
Subscribers only: Roe for Trius Therapeutics Inc's Suppliers
Subscribers only: Return On Equity for TSRX's Customers




Companies with similar Return On Equity at Jun 30 2013, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.